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tetracycline (96.4%) and gentamicin (99.3%). Staphylococci
included MRSA (35.7%) and MR-CoNS (68.4%); and MRSA iso-
lates were resistant to levoﬂoxacin (96%) and erythromycin
(74%). All clindamycin-susceptible SA had inducible resis-
tance. Dalbavancin (MIC90; 0.047mg/L) was 10-fold more
potent than vancomycin (MIC90; 0.5mg/L) against BHS.
Erythromycin susceptibility was 82% with a 25% inducible
clindamycin resistance.
Conclusions: The DECIDE study demonstrated in UK and
Ireland that dalbavancin has excellent activity and was more
potent when directly compared to vancomycin. Dalbavancin
was active against all MRSA, although the current suscepti-
bility proﬁles for other antimicrobial classes tested were of
great concern, particularly inducible clindamycin resistance
(100%). Monitoring dalbavancin activity should be continued
as this newer long-acting agent is introduced into EU clinical
practice.
doi:10.1016/j.ijid.2008.05.699
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Background: Dalbavancin activity was tested against iso-
lates from three medical centers in Italy between October
— December, 2007. Only reference quality and standardized
CLSI methods were used.
Methods: Susceptibility methods for agar diffusion were
applied by each investigator: Etest (ET; AB BIODISK) and
CLSI disk diffusion (DD) tests performed with concurrent QC
with repeated testing of strains showing unusual resistance
patterns such as linezolid, teicoplanin or dalbavancin-
non-susceptibility (MIC, >0.25mg/L). 225 strains were
tested against dalbavancin and teicoplanin by ET and
linezolid, cefoxitin, levoﬂoxacin, gentamicin, tetracycline,
erythromycin, clindamycin (plus D-test), penicillin and cef-
triaxone by DD. Dalbavancin susceptibility was deﬁned at
≤0.25mg/L.
Results: Dalbavancin showed high activity against the
151 S. aureus (SA; MIC range, ≤0.016—0.25mg/L), CoNS
(≤0.016—0.25mg/L) and -haemolytic streptococci (BHS;
≤0.016—0.094mg/L). This activity was 4-, 16- and ≥4-
fold greater than teicoplanin when comparing MIC90 values,
respectively. Susceptibility rates among SA were: linezolid
(97%), levoﬂoxacin (61%), erythromycin (43%), clindamycin
(51%), tetracycline (86%) and gentamicin (70%). Six linezolid-
non-susceptible strains were noted among SA and BHS but
all had zone diameters (19—20mm) near the breakpoint
(≥21mm). Teicoplanin-resistant CoNS and levoﬂoxacin-
resistant BHS were detected. A distinct trend toward higher
dalbavancin ET MIC results was observed, a probable techni-
cal reading error also noted for false-resistant DD linezolid
results for SA and BHS (six occurrences). D-test inducible-
resistant rates for clindamycin varied from 38 (BHS) to 78%
(SA).
Conclusions: Dalbavancin, a new long-acting glycol-
ipopeptide (once weekly dosing), demonstrated high activity
(MIC50 ranges, ≤0.016—0.19mg/L) against staphylococci and
BHS from Italy. The recorded MIC90 was 0.125mg/L, a con-
ﬁrmed ﬁnding suggesting a high MIC reading bias for ET. The
most elevated MIC results were at 0.25mg/L (breakpoint; 33
occurrences among SA). The exhibited dalbavancin potency
(4-fold greater than teicoplanin; only tested in Italy DECIDE
sample) covered all contemporary Gram-positive pathogens.
doi:10.1016/j.ijid.2008.05.700
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Background: Dalbavancin, a long-acting glycolipopep-
tide, was tested against clinical isolates from four hospitals
in Germany in the last quarter of 2007.
Methods: Investigators used standardized and reference-
quality agar diffusion methods including Etest (ET; AB
BIODISK) and CLSI disk diffusion (DD) tests with concur-
rent QC and repeated testing of strains showing unusual
resistance patterns such as linezolid resistance and van-
comycin or dalbavancin-non-susceptibility. 300 strains were
tested (200 S. aureus [SA], 40 coagulase-negative staphy-
lococci [CoNS], 60 -haemolytic streptococci [BHS] with
most being group A or S. pyogenes) against dalbavancin and
vancomycin by ET; and linezolid, cefoxitin (determination
of methicillin resistance), levoﬂoxacin, gentamicin, tetra-
cycline, erythromycin, clindamycin (plus D-test), penicillin
and ceftriaxone by DD. All German sites having acceptable
QC results were tabulated. Dalbavancin susceptibility was
deﬁned at ≤0.25mg/L.
Results: Dalbavancin exhibited excellent activity
against SA (MIC50/90, 0.047/0.125mg/L), CoNS (MIC50/90,
0.047/0.19mg/L) and BHS (MIC50/90, ≤0.016/0.032mg/L).
This activity was 16- to 32-fold greater than vancomycin.
MRSA rates were low (8%) but varied modestly from 4
to 12% among hospitals. S rates were: linezolid (100%),
levoﬂoxacin (55-83%), erythromycin (50—80%), and clin-
damycin (65—84%). D-test positive rates were 33—86% for
the SA, CoNS and BHS; overall clindamycin-resistant at
16% for SA, but nil for BHS. SA was also very susceptible
to gentamicin (95%) and tetracycline (93%). Methicillin
susceptibility or resistance did not inﬂuence dalbavancin
potency versus SA or CoNS. Highest recorded dalbavancin
MIC was 0.38mg/L, two conﬁrmed staphylococci from
Frankfurt. Some German centers read Etest results higher
(0.5—1.0 log2) than other laboratories in Europe.
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Conclusions: Dalbavancin, with a 7—8 day T1/2 (once
weekly dosing), demonstrated high potency (MIC50 ranges,
≤0.0.16—0.047mg/L) against staphylococci and BHS from
Germany. Documented dalbavancin activity (≥16-fold) was
signiﬁcantly greater than vancomycin, and dalbavancin
inhibited essentially all endemic Gram-positive pathogens
from sampled sites.
doi:10.1016/j.ijid.2008.05.701
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Background: Virulence factor production by Streptococ-
cus pyogenes is controlled by several regulatory systems.
CsrS is a negative regulatory two-component signal trans-
duction systems that inﬂuences expression of 10 to 15% of
Streptococcus pyogenes genes. Mga activates expression of
several Streptococcus pyogenes virulence genes encoding M
protein and C5a peptidase. Rgg regulates the caseinolytic
SPE B protease, M protein, C5a peptidase, the SLO cytolysin,
and streptokinase. However the association between these
regulatory factors and antibiotics susceptibility is unclear.
The objectives of this study were to determine whether
these three regulatory systems, CsrS, Mga, and Rgg inac-
tivation affects susceptibility to antibiotics.
Methods: We studied three M1 phenotype Streptococcus
pyogenes isolates (SF370, 1529, and GT01) and its derivative
CsrS knockout mutant (csrS), Mga knockout mutant (mga)
and Rgg knockout mutant (rgg). Kirby-Bauer disk-diffusion
susceptibility testing using NCCLS procedures was performed
for the following 23 antibiotics: PCG, ABP, AMP, PIPC, FRPM,
CAZ, CET, CCL, CTM, CEZ, CPZ, CMZ, VAN, IPM, MEMP, TC,
DOT, NFX, LVFX, EM, CAM, AZM, CLDM.
Results: Kirby-Bauer disk-diffusion susceptibility testing
of Streptococcus pyogenes strains showed no differences
of antibiotics susceptibility between wild-type and mga
mutant. The result of susceptibility pattern between
parental and rgg was same as that between parental
and mga mutant. However, the signiﬁcant increase of
inhibitory zones by Beta-lactam antibiotics, especially PCG,
in csrS mutant was found in comparison with parental
strain. The susceptible levels of aminoglycoside, macrolide
and lincosamide in csrS mutant were also slight higher
than those in parental strain. There was slight difference
of inhibitory zone of new quinolone between wild-type and
csrS mutant as well.
Conclusion: The result of the current study indicates that
inactivation of CsrS in Streptococcus pyogenes strain is asso-
ciated with increased susceptibility of antibiotics, especially
Beta-lactam antibiotics.
doi:10.1016/j.ijid.2008.05.702
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Objectives: Enterococci are transferred via human’s
intestinal ﬂora into sewage. The role of Enterococci have
increased as a cause of nosocomial infections. The drug of
choice for such infections is the synergic combination of cell-
wall-active agent with an aminoglycoside, most commonly
gentamicin. The prevalence of enterococcal strains display-
ing aminoglycoside resistance, cause problem in therapy. Six
genes including aac(6)-Ie-aph(2′′)-Ia, ant(4)-Ia, aph(3′′)-IIIa,
aph(2′′)-Id, aph(2′′)-Ic, aph(2′′)-Ib are responsible for caus-
ing aminoglycoside resistance and aac(6)-Ie-aph(2′′)-Ia is the
most important gene causing high-level gentamicin resis-
tance(HLGR). The spread and transferring frequencies of
these genes were evaluated among 133 enterococcal iso-
lates of medical centers and sewage treatment plants(STPs)
during 2005—2006 in Tehran.
Methods: Fifty- nine and 23 isolates of E. faecalis, E. fae-
cium from hospitals and 23, 28 isolates of E. faecalis, E.
faecium from STPs in Tehran were collected respectively.
MIC test for gentamicin and streptomycin was done with
broth micro dilution method. PCR test was performed for
detection of six genes. The ﬁlter mating method was used
for conjugation.
Results: All strains had high-level resistance to gen-
tamicin(MIC≥ 500),streptomycin and were multidrug resis-
tance(MDR). The frequencies of aac(6)-Ie-aph(2′′)-Ia gene
were 88, 96% among E. faecalis isolates from hospital,
sewage and 100, 79% for E. faecium respectively.The fre-
quencies of aph(3′′)-IIIa gene were 78,48% among E. faecalis
isolates from hospital, sewage and 70, 61% for E. faecium
respectively. None of isolates had aph(2′′)-Id, aph(2′′)-Ic,
aph(2′′)-Ib genes with the exception of one E. faecium isolate
in sewage having aph(2′′)-Ic gene. Among clinical E. faecalis
isolates, 11% had ant(4)-Ia gene. The transferring frequen-
cies of two founded genetic elements were between 10-8 -
10-9.
Conclusion: The high prevalence of aac(6)-Ie-aph(2′′)-Ia
and aph(3′′)-IIIa genes is showing circulation of these genes
among medical centers and sewage in Tehran and alarm-
ing us for changing the enterococcal infections treatment
protocols and usage of new drugs.
doi:10.1016/j.ijid.2008.05.703
